BioSpace News Archive

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt Cancer Center, it has commenced treatment of the third patient in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

Brain Navi announced the demonstration of NaoTrac, a neurosurgical navigation robot and KrystoLens, a single-use neuro-endoscope at CNS 2023 in Washington D.C. and EANS 2023 in Barcelona, respectively.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four presentations in Parkinson’s disease (PD) will be shared at the International Congress of Parkinson’s Disease and Movement Disorder Society (MDS), being held in Copenhagen, Denmark, August 27-31.

Prime Therapeutics LLC /Magellan Rx is proud to announce that Magellan Rx Pharmacy, LLC, MRx’s specialty pharmacy, has earned URAC reaccreditation for Specialty Pharmacy.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, September 11th through Wednesday, September 13th starting at 7:00 a.m. ET.

Tivic Health® Systems, Inc. announced that the Company has entered into a non-exclusive agreement with AmerisourceBergen, soon to be Cencora, to make Tivic’s products available on AmerisourceBergen’s third-party marketplace.

Akston Biosciences Corporation, which invents, develops and manufactures breakthrough protein therapeutics for Companion Animal Health, announced that President & CEO Todd Zion, Ph.D., will present at the 2023 Animal Health Summit in Kansas City, MO on August 28, 2023.

City of Hope is the first health system in Southern California to offer patients diagnosed with primary or metastatic lung and bone cancer a new form of radiotherapy that can detect and treat multiple tumors in real time using precision targeting.

Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Empyrean Medical Systems, Inc. (“Empyrean”), MagCorp Inc. (“MagCorp”), and MetOx Technologies, Inc. (“MetOx”) today announced a strategic collaboration agreement to accelerate the large-scale development of novel technology that will enable commercial production of next generation, state-of-the-art radiation therapy technology for cancer treatment.